Spots Global Cancer Trial Database for mcrc
Every month we try and update this database with for mcrc cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| Biomarker Directed Treatment in Metastatic Colorectal Cancer | NCT01703390 | Metastatic Colo... | FOLFIRI + Cetux... modifiedFOLFOX6... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy | NCT03305913 | Pretreated Meta... | TAS 102 Regorafenib | 18 Years - | AIO-Studien-gGmbH | |
| FOLFIRI and Sunitinib in Metastatic Colorectal Cancer | NCT00806663 | Metastatic Colo... Liver Metastase... | sunitinib added... | 18 Years - 80 Years | Central European Society for Anticancer Drug Research | |
| Study of Durvalumab and Tremelimumab After Radiation for Microsatellite Stable Metastatic Colorectal Cancer Progressing on Chemotherapy | NCT03007407 | Colorectal Canc... | durvalumab Tremelimumab | 18 Years - | NSABP Foundation Inc | |
| Trial in Metastatic Colorectal Cancer With FOLFIRI Plus Aflibercept as First Line Treatment | NCT02624726 | Metastatic Colo... | 5 Fluorouracil Leucovorin Irinotecan Aflibercept | 18 Years - | Hellenic Oncology Research Group | |
| LifePearl-Iri Pharmacokinetic Study | NCT02547480 | Metastatic Colo... mCRC | TACE with irino... | 18 Years - | Terumo Europe N.V. | |
| XELOX/mFOLFOX Plus Vitamin D3 vs. XELOX/mFOLFOX as Firstline Chemotherapy in mCRC | NCT03389659 | Vitamin D3 | vitamin D3 Placebo | 18 Years - | Tianjin Medical University Cancer Institute and Hospital | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation | NCT05127759 | Metastatic Colo... mCRC | HLX208 | 18 Years - | Shanghai Henlius Biotech | |
| A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours | NCT06147037 | Advanced Solid ... Metastatic Colo... Head and Neck S... Non-small Cell ... Pancreatic Duct... | FPI-2053 [111In]-FPI-210... [225Ac]-FPI-206... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer | NCT03567629 | mCRC | Irinotecan Oxaliplatin | 18 Years - | Peking University | |
| An Observational Study to Learn More About the Long-Term Responses to Treatment With Regorafenib in Patients With Metastatic Colorectal Cancer in the United States | NCT06029010 | Metastatic Colo... | Regorafenib (St... | 18 Years - | Bayer | |
| Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO) | NCT01507545 | Metastatic Colo... Colorectal Canc... | MORAb-004 Placebo Best supportive... | 18 Years - | Morphotek | |
| Optimal Anti-EGFR Treatment of mCRC Patients With Low-Frequency RAS Mutation | NCT04034173 | Treatment Relat... | Panitumumab Irinotecan Folinic acid 5-FU | 18 Years - | Ludwig-Maximilians - University of Munich | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. | NCT02469480 | Metastatic Colo... | FerInject Ferro sanol | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| A Study of BBI608 Administrated With FOLFIRI + Bevacizumab in Adult Patients With Metastatic Colorectal Cancer | NCT02641873 | Metastatic Colo... | BBI608 5-FU Irinotecan Levofolinate Bevacizumab | 20 Years - | Sumitomo Pharma Co., Ltd. | |
| Biomarker Analysis for Patients With Metastatic Colorectal Cancer (MCC) | NCT01909362 | Colorectal Neop... Advanced Metast... | 18 Years - | US Oncology Research | ||
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | NCT04317599 | BRAF V600E Muta... Metastatic Colo... | Non Interventio... | 18 Years - | Pierre Fabre Medicament | |
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | NCT04034459 | Metastatic Colo... | Bevacizumab Irinotecan Folinic acid Oxaliplatin 5-FU Cetuximab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Regorafenib in Combination With TAS-102 in Subjects With Metastatic Colorectal Cancer Who Have Progressed After Standard Therapy | NCT03305913 | Pretreated Meta... | TAS 102 Regorafenib | 18 Years - | AIO-Studien-gGmbH | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | NCT02301104 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy | NCT00332163 | Metastatic Colo... Skin Rash Skin Toxicities Colon Cancer Colorectal Canc... | Panitumumab Irinotecan FOLFIRI Pre-emptive Ski... Reactive Skin T... | 18 Years - 90 Years | Amgen | |
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | NCT00418938 | Cancer Colon Cancer Colorectal Canc... Metastatic Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Amgen | |
| Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) | NCT03043950 | Metastatic Colo... RAS Wild-type | Panitumumab | 18 Years - | iOMEDICO AG | |
| A Study of Overall Survival in Participants With Metastatic Colorectal Cancer (mCRC) | NCT05420909 | Metastatic Colo... | 18 Years - | Bristol-Myers Squibb | ||
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Evaluate the Efficacy of Irinotecan Versus Oxaliplatin in the First-line Treatment of Refractory Metastatic Colorectal Cancer | NCT03567629 | mCRC | Irinotecan Oxaliplatin | 18 Years - | Peking University | |
| Sulfasalazine in Patients With Metastatic Colorectal Cancer | NCT06134388 | Metastatic Colo... | Sulfasalazine | 18 Years - 65 Years | Tanta University | |
| Biomarker Directed Treatment in Metastatic Colorectal Cancer | NCT01703390 | Metastatic Colo... | FOLFIRI + Cetux... modifiedFOLFOX6... | 18 Years - | Arbeitsgemeinschaft medikamentoese Tumortherapie | |
| A Study of Fruquintinib in Combination With Tislelizumab in Advanced Solid Tumors | NCT04577963 | Triple Negative... Endometrial Can... Solid Tumor, Un... Colorectal Canc... | Fruquintinib Tislelizumab | 18 Years - | Hutchmed | |
| A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment | NCT02301104 | Advanced Solid ... | TAS-102 | 18 Years - | Taiho Oncology, Inc. | |
| Validation of a New Prognostic Score for Adult Patients With RAS Wild-type mCRC Treated With Vectibix® and FOLFIRI or FOLFOX in First Line (VALIDATE) | NCT03043950 | Metastatic Colo... RAS Wild-type | Panitumumab | 18 Years - | iOMEDICO AG | |
| Tislelizumab Combined With Fruquintinib for Metastatic pMMR/MSS Colorectal Cancer | NCT05690035 | Metastatic Colo... mCRC | Tislelizumab & ... | 18 Years - 80 Years | Sun Yat-sen University | |
| LifePearl-Iri Pharmacokinetic Study | NCT02547480 | Metastatic Colo... mCRC | TACE with irino... | 18 Years - | Terumo Europe N.V. | |
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | NCT00418938 | Cancer Colon Cancer Colorectal Canc... Metastatic Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Amgen | |
| A Study in Second Line Metastatic Colorectal Cancer | NCT01183780 | Colorectal Canc... | Ramucirumab Placebo Irinotecan Folinic Acid 5-Fluorouracil | 18 Years - | Eli Lilly and Company | |
| A Retrospective Non Interventional Study on First Line Treatment for Patients With BRAFV600E Mutant Metastatic Colorectal Cancer (mCRC) | NCT04317599 | BRAF V600E Muta... Metastatic Colo... | Non Interventio... | 18 Years - | Pierre Fabre Medicament | |
| SBRT Sequential CapeOX Regimen Combined With Bevacizumab and Sintilimab in First-line Treatment of mCRC | NCT05438108 | Metastatic Colo... | SBRT Sequential... | 18 Years - 75 Years | Huazhong University of Science and Technology | |
| Assessment of Clinical Practice Administration of Chemotherapy and Anti-angiogenic Agent (Bevacizumab) in Colorectal Cancer | NCT01811108 | Metastatic Colo... | 18 Years - | Hellenic Oncology Research Group | ||
| Study Evaluating the Safety and Efficacy of FOLFIRI Plus Cetuximab or FOLFOX Plus Cetuximab as First-line Therapy in Subjects With KRAS Wild-type Metastatic Colorectal Cancer (APEC-Study) | NCT00778830 | Metastatic Colo... | Cetuximab FOLFIRI FOLFOX | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | NCT06255379 | Metastasis Colo... Colon Cancer Rectal Cancer | Fuquinitinib+Te... | 18 Years - 75 Years | Guangzhou University of Traditional Chinese Medicine | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany | ||
| QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine | NCT03563157 | Colorectal Canc... mCRC | Aldoxorubicin H... ALT-803 ETBX-011 ETBX-021 ETBX-051 ETBX-061 GI-4000 GI-6207 GI-6301 haNK Avelumab Capecitabine Cetuximab Cyclophosphamid... 5-Fluorouracil Leucovorin Nab-paclitaxel Oxaliplatin Regorafenib SBRT | 18 Years - | ImmunityBio, Inc. | |
| Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. | NCT02469480 | Metastatic Colo... | FerInject Ferro sanol | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial | NCT00418938 | Cancer Colon Cancer Colorectal Canc... Metastatic Canc... Rectal Cancer Metastatic Colo... | Panitumumab Bevacizumab Leucovorin Irinotecan 5-Fluorouracil | 18 Years - | Amgen | |
| A Study Of PF-05212384 Plus Irinotecan Vs Cetuximab Plus Irinotecan In Patients With KRAS And NRAS Wild Type Metastatic Colorectal Cancer | NCT01925274 | Metastatic Colo... | PF-05212384 irinotecan Cetuximab Irinotecan | 18 Years - | Pfizer | |
| QL1101 in Combination With JS001 in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer | NCT04527068 | Refractory Meta... pMMR MSS | Bevacizumab Tripleitriumab | 18 Years - 75 Years | Second Affiliated Hospital, School of Medicine, Zhejiang University | |
| Trial of FOLF(HA)Iri Versus FOLFIRI in mCRC | NCT01290783 | Metastatic Colo... | Irintoecan HA-Irinotecan s... | 18 Years - | Alchemia Oncology | |
| A Retrospective Review of Liver Resection Rate in Metastatic Colorectal Cancer Patients Following Downsizing Treatment With Chemotherapy Plus Cetuximab in Normal UK National Health Service Clinical Practice | NCT01460745 | Metastatic Colo... | 18 Years - | Merck KGaA, Darmstadt, Germany | ||
| Cetuximab Plus Irinotecan in Patients With NeoRAS Wild-type Metastatic Colorectal Cancer In Third-line Therapy | NCT05962502 | Metastatic Colo... | Cetuximab and i... | 18 Years - | Sun Yat-sen University | |
| Phase II Study of Perindopril and Regorafenib in mCRC | NCT02651415 | Metastatic Colo... | Regorafenib Perindopril | 18 Years - | British Columbia Cancer Agency | |
| MEN1611 With Cetuximab in Metastatic Colorectal Cancer (C-PRECISE-01) | NCT04495621 | Metastatic Colo... | MEN1611 Cetuximab | 18 Years - | Menarini Group | |
| Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer | NCT06255379 | Metastasis Colo... Colon Cancer Rectal Cancer | Fuquinitinib+Te... | 18 Years - 75 Years | Guangzhou University of Traditional Chinese Medicine | |
| A Non-Interventional Follow-Up to the VELOUR Study - Translational Research | NCT01754272 | Metastatic Colo... | 18 Years - | KU Leuven | ||
| FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | NCT04034459 | Metastatic Colo... | Bevacizumab Irinotecan Folinic acid Oxaliplatin 5-FU Cetuximab | 18 Years - | Ludwig-Maximilians - University of Munich | |
| Safety, Efficacy, and Dosing of Stereotactic Radiosurgery for Hepato-cellular Carc/Colo-rectal Liver Metastases | NCT01528878 | Liver Neoplasms Colonic Neoplas... Metastatic Canc... | Stereotactic Ra... | 18 Years - | UNC Lineberger Comprehensive Cancer Center | |
| Intravenous Ferric Carboxymaltose vs. Oral Iron Substitution in Patients With Metastatic Colorectal Cancer (CRC) and Iron Deficiency Anemia: a Randomized Multicenter Treatment Optimization Study. | NCT02469480 | Metastatic Colo... | FerInject Ferro sanol | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Participants With Metastatic Colorectal Cancer | NCT04322539 | Metastatic Colo... Metastatic Colo... | Fruquintinib Placebo | 18 Years - | Hutchmed | |
| A Post-Marketing Surveillance Study On Erbitux® (Cetuximab) In Patients With Metastatic Colorectal Cancer Refractory To Irinotecan Containing Treatment | NCT01134640 | Metastatic Colo... | - | Merck KGaA, Darmstadt, Germany |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
